Treating Diabetes: Designing the Once-Weekly and Oral GLP-1 Semaglutide

Since the early clinical findings of using glucagon like peptide-1 (GLP-1) to regulate blood glucose levels in the late 80´s there has been an increasing interest to discover and develop GLP-1 receptor agonists for treatment of type 2 diabetes. The increased non-clinical and clinical understanding of the mechanism of action of GLP-1 and the parallel technical development have now brought the scientific community to a very high level of understanding with structural insight of the interaction of peptides and small molecules with GPCR class B receptors.

Join Jesper Lau, Vice President of Research Chemistry at Novo Nordisk A/S, during this free interactive broadcast to learn why the discovery of Semaglutide is a fantastic example of how technology and biologic understanding have developed a superior peptide for treatment of diabetes.

What You Will Learn

  • How to tailor pharmacokinetic and pharmacodynamic properties of an inherent short action GLP-1 peptide to fit for once weekly dosing
  • A solution to oral dosing of a GLP-1 peptide
  • The best in class clinical performance on blood glucose and weight loss

Jesper Lau
Novo Nordisk A/S

Puneet Tyagi